title: Personalized treatment of hepatitis B.
abstract: There are seven approved drugs for treatment of hepatitis B. Professional guidelines provide a framework for managing patients but these guidelines should be interpreted in the context of the individual patient's clinical and social circumstances. Personalized management of hepatitis B can be applied based on prediction of the individual patient's risk of cirrhosis and hepatocellular carcinoma to guide the frequency and intensity of monitoring and urgency of treatment. It can also be applied to decisions regarding when to start treatment, which drug to use, and when to stop based on the individual patient's disease characteristics, preference, comorbidities and other mitigating circumstances.
authors.affiliation: Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Anna S
authors.initials: AS
authors.lastname: Lok
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005838:Genotype; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D008107:Liver Diseases / Q000209:etiology; D057285:Precision Medicine; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents
keywords: Chronic hepatitis B; Hepatitis B virus; Management; Personalized medicine
references.citation: Gastroenterology. 2012 Sep;143(3):629-36.e1
references.pmid: 22659218
references.citation: Gut. 2015 Aug;64(8):1289-95
references.pmid: 25011935
references.citation: Clin Gastroenterol Hepatol. 2014 Jan;12(1):16-26
references.pmid: 23660419
references.citation: Gastroenterology. 2009 Dec;137(6):2002-9
references.pmid: 19737568
references.citation: Clin Gastroenterol Hepatol. 2015 Feb;13(2):377-385.e5
references.pmid: 24993366
references.citation: Lancet. 2013 Feb 9;381(9865):468-75
references.pmid: 23234725
references.citation: J Clin Oncol. 2010 Apr 1;28(10):1660-5
references.pmid: 20194845
references.citation: J Hepatol. 2009 Jan;50(1):80-8
references.pmid: 18977053
references.citation: J Viral Hepat. 2007 Mar;14(3):147-52
references.pmid: 17305879
references.citation: Hepatol Int. 2012 Jun;6(3):531-61
references.pmid: 26201469
references.citation: Gastroenterology. 2013 May;144(5):933-44
references.pmid: 23415803
references.citation: Liver Int. 2015 Jan;35 Suppl 1:100-6
references.pmid: 25529094
references.citation: J Clin Oncol. 2010 May 10;28(14):2437-44
references.pmid: 20368541
references.citation: Hepatology. 2009 Sep;50(3):661-2
references.pmid: 19714720
references.citation: Hepatology. 2013 Aug;58(2):546-54
references.pmid: 23504622
references.citation: Hepatology. 2013 Dec;58(6):1888-96
references.pmid: 23744454
references.citation: N Engl J Med. 2004 Oct 7;351(15):1521-31
references.pmid: 15470215
references.citation: Hepatology. 2014 Feb;59(2):434-42
references.pmid: 23939953
references.citation: Gastroenterology. 2014 Jan;146(1):15-9
references.pmid: 24275236
references.citation: J Hepatol. 2012 Jul;57(1):167-85
references.pmid: 22436845
references.citation: Hepatology. 2009 May;49(5):1503-14
references.pmid: 19280622
references.citation: Clin Gastroenterol Hepatol. 2015 Feb;13(2):386-9
references.pmid: 25158927
references.citation: JAMA. 2006 Jan 4;295(1):65-73
references.pmid: 16391218
references.citation: Gastroenterology. 2014 Jan;146(1):138-146.e5
references.pmid: 24067879
references.citation: Lancet Oncol. 2011 Jun;12(6):568-74
references.pmid: 21497551